We’ve updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
What is the projected value of the rare neurological disease treatment market by 2029?
The rare neurological disease treatment market size has grown strongly in recent years. It will grow from $9.85 billion in 2024 to $10.68 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to biosimilars in rare disease treatment, globalization of clinical trials, healthcare reimbursement policies, orphan drug designations, advancements in genetic research
The rare neurological disease treatment market size is expected to see strong growth in the next few years. It will grow to $14.84 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to improved diagnostic tools, precision medicine advancements, patient-centric drug development, integration of real-world evidence, telemedicine for patient support, shift towards personalized therapies. Major trends in the forecast period include technological innovations, ai in drug discovery, blockchain for data security, machine learning in drug discovery.
Download Your Free Sample PDF:
How are technological advancements fueling growth in the rare neurological disease treatment market?
The prevalence of rare neurological diseases is expected to propel the growth of the rare neurological disease treatment market going forward. Rare neurological diseases refer to low-prevalence neurological disorders, including Huntington's disease, ALS (amyotrophic lateral sclerosis), Rett syndrome, and various forms of muscular dystrophy. Treating rare neurological diseases involves multiple approaches to manage symptoms, slow disease progression, and improve the quality of life for individuals affected by these conditions. For instance, in January 2023, according to an article published by BioMed Central Ltd., a UK-based publisher of open-access scientific journals, the collective prevalence of Rett syndrome was determined to be 7.1 per 100,000 females in a combined sample size of 9.57 million women, with a total of 673 confirmed cases. Therefore, the prevalence of rare neurological diseases is driving the growth of the rare neurological disease treatment market.
Which segment currently leads the rare neurological disease treatment market in terms of revenue share?
The rare neurological disease treatment market covered in this report is segmented –
1) By Drug Type: Biologics, Small Molecules
2) By Therapy: Cognitive Behavioral Therapy, Interpersonal Psychotherapy, Cyberknife, Other Therapies
3) By Mode Of Administration: Oral, Injectable, Other Modes Of Administration
4) By Disorders: Aicardi Syndrome, Aicardi-Goutières Syndrome, Reflex Sympathetic Dystrophy Syndrome, Battaglia-Neri Syndrome, Creutzfeldt Jakob Disease, Agnosia, Other Disorders
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies And Drug Store, Online Pharmacies
Subsegments:
1) By Biologics: Monoclonal Antibodies, Gene Therapies, Recombinant Proteins
2) By Small Molecules: Targeted Small Molecules, Neuroprotective Agents, Anti-inflammatory Small Molecules
View The Full Market Report:
What technological trends are expected to redefine the rare neurological disease treatment market?
The development of orphan pharmaceuticals is a key trend gaining popularity in the rare neurological disease treatment market. Major companies operating in the rare neurological disease treatment sector are focused on developing innovative and specialized treatments to strengthen their position in the market. For instance, in April 2023, Orphalan SA, a French orphan drug development company, introduced Cuvrior, a novel trientine tetrahydrochloride (TETA-4HCl), in the European market. Cuvrior is now commercially available for treating adult patients with stable Wilson disease who have undergone copper reduction therapy and have shown tolerance to D-penicillamine. The drug received approval from the United States Food and Drug Administration (FDA) and was granted orphan drug exclusivity (ODE) in April 2022 for this specific patient population.
Who are the top competitors in the global rare neurological disease treatment market?
Major companies operating in the rare neurological disease treatment market include Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd, Bayer AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi-Aventis SA, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Medtronic PLC, Teva Pharmaceutical Industries Ltd., CSL Limited, Biogen Inc., UCB S.A., Eisai Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Jazz Pharmaceuticals PLC, Mitsubishi Tanabe Pharma Corporation, Neurocrine Biosciences Inc., Kedrion Biopharma Inc., Merz Pharma GmbH & Co. KGaA, Harmony Biosciences Holdings Inc., Amicus Therapeutics Inc., Revance Therapeutics Inc., Aquestive Therapeutics Inc., US WorldMeds LLC (Solstice Neurosciences LLC), Stoke Therapeutics Inc., Retrotope Inc.
What regional dynamics are shaping the future of the global rare neurological disease treatment market?
North America was the largest region in the rare neurological diseases treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare neurological disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Rare Neurological Disease Treatment Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
Need Customized Data On Rare Neurological Disease Treatment Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you're entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment